Mabel Toribio, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 23 | 2024 | 17569 | 1.590 |
Why?
|
| Cardiovascular System | 2 | 2023 | 841 | 0.870 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2024 | 165 | 0.810 |
Why?
|
| Heart Failure, Diastolic | 1 | 2019 | 77 | 0.630 |
Why?
|
| Arteritis | 2 | 2017 | 159 | 0.600 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2024 | 1815 | 0.520 |
Why?
|
| Hormones | 1 | 2019 | 866 | 0.510 |
Why?
|
| Anti-Retroviral Agents | 5 | 2020 | 1789 | 0.500 |
Why?
|
| Monocytes | 3 | 2022 | 2605 | 0.500 |
Why?
|
| Pravastatin | 1 | 2017 | 393 | 0.480 |
Why?
|
| Quinolines | 2 | 2018 | 772 | 0.480 |
Why?
|
| Cardiomyopathies | 4 | 2023 | 2056 | 0.460 |
Why?
|
| Macrophages | 3 | 2024 | 5799 | 0.440 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2022 | 1551 | 0.430 |
Why?
|
| Triglycerides | 2 | 2020 | 2464 | 0.410 |
Why?
|
| Vascular Diseases | 1 | 2020 | 1162 | 0.390 |
Why?
|
| Cardiology | 1 | 2023 | 1702 | 0.390 |
Why?
|
| Heart | 4 | 2023 | 4446 | 0.390 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2022 | 2145 | 0.380 |
Why?
|
| HIV | 5 | 2023 | 1597 | 0.380 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 1820 | 0.360 |
Why?
|
| Myocardium | 2 | 2020 | 4788 | 0.340 |
Why?
|
| Stroke Volume | 2 | 2022 | 5622 | 0.320 |
Why?
|
| Proteomics | 3 | 2023 | 3912 | 0.320 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 1904 | 0.320 |
Why?
|
| Atherosclerosis | 2 | 2022 | 3433 | 0.310 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1596 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 3251 | 0.280 |
Why?
|
| Heart Failure | 5 | 2023 | 11879 | 0.270 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 2024 | 128 | 0.210 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 15662 | 0.210 |
Why?
|
| Anticholesteremic Agents | 2 | 2017 | 972 | 0.170 |
Why?
|
| Fibrosis | 3 | 2023 | 2080 | 0.170 |
Why?
|
| Policy | 1 | 2023 | 513 | 0.160 |
Why?
|
| Arteries | 1 | 2024 | 1127 | 0.160 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2023 | 545 | 0.160 |
Why?
|
| Transsexualism | 1 | 2022 | 210 | 0.160 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 3941 | 0.150 |
Why?
|
| Simian immunodeficiency virus | 1 | 2023 | 814 | 0.150 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 40 | 0.150 |
Why?
|
| Humans | 29 | 2024 | 768166 | 0.130 |
Why?
|
| Weight Gain | 2 | 2023 | 2359 | 0.130 |
Why?
|
| Aorta | 2 | 2020 | 2045 | 0.120 |
Why?
|
| Female | 17 | 2024 | 397192 | 0.120 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 590 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2020 | 1191 | 0.120 |
Why?
|
| Middle Aged | 14 | 2024 | 223492 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2020 | 1903 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2020 | 22291 | 0.110 |
Why?
|
| Inflammation | 3 | 2019 | 10873 | 0.110 |
Why?
|
| Biological Transport | 1 | 2017 | 2085 | 0.110 |
Why?
|
| Anti-HIV Agents | 3 | 2020 | 4573 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 3780 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2023 | 54926 | 0.100 |
Why?
|
| Osteopontin | 2 | 2023 | 306 | 0.090 |
Why?
|
| Adult | 10 | 2024 | 223646 | 0.090 |
Why?
|
| Proteome | 1 | 2020 | 1890 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1907 | 0.090 |
Why?
|
| Male | 12 | 2024 | 364719 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 1883 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 2298 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2024 | 4530 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 2403 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2020 | 2596 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2017 | 1982 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2024 | 12465 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 36743 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5520 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2017 | 3080 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2020 | 8543 | 0.060 |
Why?
|
| Sex Factors | 1 | 2018 | 10632 | 0.060 |
Why?
|
| Allostasis | 1 | 2024 | 76 | 0.060 |
Why?
|
| Aged | 5 | 2023 | 171504 | 0.050 |
Why?
|
| HIV-1 | 1 | 2019 | 6961 | 0.050 |
Why?
|
| Macaca | 1 | 2023 | 413 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2017 | 19015 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 13490 | 0.050 |
Why?
|
| Obesity | 1 | 2023 | 13090 | 0.050 |
Why?
|
| Aging | 1 | 2020 | 8744 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 461 | 0.040 |
Why?
|
| Proteinuria | 1 | 2023 | 611 | 0.040 |
Why?
|
| Placebos | 1 | 2024 | 1667 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2022 | 652 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 12252 | 0.040 |
Why?
|
| Viral Load | 2 | 2020 | 3396 | 0.040 |
Why?
|
| Risk Factors | 3 | 2024 | 74944 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 6568 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2024 | 1758 | 0.040 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2017 | 67 | 0.040 |
Why?
|
| Mannans | 1 | 2017 | 58 | 0.030 |
Why?
|
| Immunity | 1 | 2023 | 1003 | 0.030 |
Why?
|
| Mannose-Binding Lectins | 1 | 2017 | 101 | 0.030 |
Why?
|
| Gender Identity | 1 | 2022 | 770 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2024 | 1841 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 26379 | 0.030 |
Why?
|
| Estradiol | 1 | 2022 | 1951 | 0.030 |
Why?
|
| Birth Weight | 1 | 2023 | 2121 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2024 | 65371 | 0.030 |
Why?
|
| Dextrans | 1 | 2017 | 574 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 82029 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2023 | 13053 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2023 | 4146 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 594 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2021 | 81762 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2023 | 4176 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2022 | 2059 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 1960 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2024 | 2819 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 3109 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 169246 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 3231 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 3409 | 0.020 |
Why?
|
| Young Adult | 3 | 2023 | 60066 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2020 | 3329 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 2819 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2017 | 6340 | 0.020 |
Why?
|
| Liver | 1 | 2023 | 7577 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 2735 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 14783 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2017 | 3474 | 0.020 |
Why?
|
| Research Design | 1 | 2020 | 6211 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2023 | 26422 | 0.010 |
Why?
|
| Adolescent | 2 | 2023 | 89169 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1987 | 1617 | 0.010 |
Why?
|
| United States | 2 | 2023 | 73039 | 0.010 |
Why?
|
| Pregnancy | 1 | 2023 | 30256 | 0.010 |
Why?
|
| Infant | 1 | 2023 | 36535 | 0.010 |
Why?
|
| Prevalence | 1 | 2018 | 15869 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1987 | 2204 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 30238 | 0.010 |
Why?
|
| Child | 1 | 2023 | 80917 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 59629 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1987 | 10266 | 0.010 |
Why?
|
| AIDS-Related Complex | 1 | 1987 | 107 | 0.000 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1987 | 897 | 0.000 |
Why?
|
| Lymphopenia | 1 | 1987 | 300 | 0.000 |
Why?
|